Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET LEXINGTON, Mass., April 26,…
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET LEXINGTON, Mass., April 26,…
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) today announced it will…
Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid…
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical…
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now…
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice”…
JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage…
Gastric cancer is the third most common cause of cancer related death in the world…
Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within…
Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR) WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE)…
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (“TLIS”), a company…
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
Rajan, Sims bring unique platform technology experience to help build the next generation of RNA…
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women’s…
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)…
Webinar to feature presentations from Harold Bays, MD, and Deepak L. Bhatt, MD, MPH, on…